MedTrace Logo

Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

NCT00483327 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated endometrial carcinoma.

Conditions

  • Atypical Endometrial Hyperplasia
  • Endometrial Carcinoma

Interventions

DRUG

Megestrol Acetate

Sponsors & Collaborators

Principal Investigators

  • Stephanie V Blank, M.D. · New York University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483327 on ClinicalTrials.gov